CO2017004517A2 - Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration - Google Patents
Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaborationInfo
- Publication number
- CO2017004517A2 CO2017004517A2 CONC2017/0004517A CO2017004517A CO2017004517A2 CO 2017004517 A2 CO2017004517 A2 CO 2017004517A2 CO 2017004517 A CO2017004517 A CO 2017004517A CO 2017004517 A2 CO2017004517 A2 CO 2017004517A2
- Authority
- CO
- Colombia
- Prior art keywords
- carbazole
- carboxamide
- inhibitors
- methods
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se revelan los compuestos de la fórmula (I): o una de sus sales, en donde: Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, y R7d se definen en la presente. También se revelan métodos de uso de tales compuestos como inhibidores de la tirosina cinasa de Bruton (Btk) y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son de utilidad en el tratamiento, prevención o lentificación de la progresión de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunes y enfermedad vascular.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068234P | 2014-10-24 | 2014-10-24 | |
PCT/US2015/057077 WO2016065236A1 (en) | 2014-10-24 | 2015-10-23 | Carbazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017004517A2 true CO2017004517A2 (es) | 2017-08-31 |
Family
ID=54427879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0004517A CO2017004517A2 (es) | 2014-10-24 | 2017-05-04 | Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration |
Country Status (33)
Country | Link |
---|---|
US (3) | US10266491B2 (es) |
EP (1) | EP3209651B9 (es) |
JP (1) | JP6599983B2 (es) |
KR (1) | KR102514914B1 (es) |
CN (1) | CN107074804B (es) |
AR (1) | AR102427A1 (es) |
AU (1) | AU2015335703B2 (es) |
BR (1) | BR112017007545A2 (es) |
CA (1) | CA2965523A1 (es) |
CL (1) | CL2017001001A1 (es) |
CO (1) | CO2017004517A2 (es) |
CY (1) | CY1122549T1 (es) |
DK (1) | DK3209651T3 (es) |
EA (1) | EA032361B1 (es) |
ES (1) | ES2761903T3 (es) |
HR (1) | HRP20192197T2 (es) |
HU (1) | HUE048321T2 (es) |
IL (1) | IL251798B (es) |
LT (1) | LT3209651T (es) |
MA (1) | MA40302B1 (es) |
ME (1) | ME03754B (es) |
MX (1) | MX2017005255A (es) |
MY (1) | MY190568A (es) |
PE (1) | PE20171239A1 (es) |
PH (1) | PH12017500724A1 (es) |
PL (1) | PL3209651T3 (es) |
PT (1) | PT3209651T (es) |
RS (1) | RS59707B1 (es) |
SG (2) | SG11201703187PA (es) |
SI (1) | SI3209651T1 (es) |
TN (1) | TN2017000158A1 (es) |
TW (1) | TWI676618B (es) |
WO (1) | WO2016065236A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3210973T (pt) | 2014-10-24 | 2021-02-12 | Takeda Pharmaceuticals Co | Compostos de heteroarilo para o tratamento de doenças oftálmicas |
WO2016065222A1 (en) * | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
WO2018009017A1 (en) * | 2016-07-07 | 2018-01-11 | Daewoong Pharmaceutical Co., Ltd. | NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
EP3694528A4 (en) | 2017-10-13 | 2021-07-28 | The Regents of the University of California | MTORC1 MODULATORS |
CN109053542A (zh) * | 2018-07-25 | 2018-12-21 | 南通大学 | 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法 |
CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法 |
EP4157446A1 (en) * | 2020-06-02 | 2023-04-05 | GB002, Inc. | Kinase inhibitors |
CN115232061B (zh) * | 2021-09-18 | 2024-01-30 | 山西紫罗蓝新材料科技有限公司 | 一种3-硝基-9-乙基咔唑粗产物的提取工艺 |
WO2024010784A1 (en) * | 2022-07-06 | 2024-01-11 | Vividion Therapeutics, Inc. | Pharmaceutical compositions comprising wrn helicase inhibitors |
WO2024073587A1 (en) * | 2022-09-29 | 2024-04-04 | Vividion Therapeutics, Inc. | N-acryloylmorpholine derivatives as keap1 modulators and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
CA2587192A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
MX2007007345A (es) | 2004-12-17 | 2007-09-07 | Glenmark Pharmaceuticals Sa | Compuestos heterociclicos novedosos utiles para el tratamiento de trastornos inflamatorios y alergicos. |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2007061764A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Tricyclic compounds useful as inhibitors of kinases |
US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
US8263648B2 (en) | 2006-09-11 | 2012-09-11 | Mylan Laboratories Ltd. | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 |
US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
CA2707491A1 (en) | 2007-12-13 | 2009-06-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
PL2247558T3 (pl) | 2008-02-14 | 2022-05-02 | Eli Lilly And Company | Nowe środki obrazujące do wykrywania czynnościowych zaburzeń neurologicznych |
GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
JP2011524893A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
MX2011006171A (es) * | 2008-12-19 | 2011-06-20 | Squibb Bristol Myers Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa. |
CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
EP2415184B1 (en) | 2009-02-13 | 2019-04-10 | Nextivity, Inc. | Remote control for booster |
WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
WO2012066442A1 (en) | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
CA2834077A1 (en) | 2011-05-17 | 2012-11-22 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
TW201728592A (zh) | 2012-01-10 | 2017-08-16 | 林伯士艾瑞斯公司 | Irak抑制劑及其用途 |
MX2015002975A (es) | 2012-10-26 | 2015-06-22 | Hoffmann La Roche | Inhibidores de la tirosina cinasa de bruton. |
TWI648272B (zh) * | 2013-06-25 | 2019-01-21 | 美商必治妥美雅史谷比公司 | 經取代之四氫咔唑及咔唑甲醯胺化合物 |
US9714234B2 (en) * | 2013-06-25 | 2017-07-25 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds |
WO2016065222A1 (en) * | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
MY188048A (en) | 2014-10-24 | 2021-11-12 | Bristol Myers Squibb Co | Indole carboxamide compounds useful as kinase inhibitors |
-
2015
- 2015-10-23 PE PE2017000741A patent/PE20171239A1/es unknown
- 2015-10-23 AR ARP150103455A patent/AR102427A1/es unknown
- 2015-10-23 DK DK15790408.7T patent/DK3209651T3/da active
- 2015-10-23 BR BR112017007545A patent/BR112017007545A2/pt not_active Application Discontinuation
- 2015-10-23 CA CA2965523A patent/CA2965523A1/en active Pending
- 2015-10-23 MY MYPI2017701432A patent/MY190568A/en unknown
- 2015-10-23 WO PCT/US2015/057077 patent/WO2016065236A1/en active Application Filing
- 2015-10-23 SG SG11201703187PA patent/SG11201703187PA/en unknown
- 2015-10-23 LT LTEP15790408.7T patent/LT3209651T/lt unknown
- 2015-10-23 PL PL15790408T patent/PL3209651T3/pl unknown
- 2015-10-23 EA EA201790745A patent/EA032361B1/ru not_active IP Right Cessation
- 2015-10-23 SG SG10201903619YA patent/SG10201903619YA/en unknown
- 2015-10-23 TN TN2017000158A patent/TN2017000158A1/en unknown
- 2015-10-23 RS RS20191645A patent/RS59707B1/sr unknown
- 2015-10-23 TW TW104134975A patent/TWI676618B/zh not_active IP Right Cessation
- 2015-10-23 SI SI201530981T patent/SI3209651T1/sl unknown
- 2015-10-23 MX MX2017005255A patent/MX2017005255A/es active IP Right Grant
- 2015-10-23 EP EP15790408.7A patent/EP3209651B9/en active Active
- 2015-10-23 JP JP2017522120A patent/JP6599983B2/ja active Active
- 2015-10-23 HU HUE15790408A patent/HUE048321T2/hu unknown
- 2015-10-23 KR KR1020177013606A patent/KR102514914B1/ko active IP Right Grant
- 2015-10-23 US US15/521,194 patent/US10266491B2/en active Active
- 2015-10-23 AU AU2015335703A patent/AU2015335703B2/en not_active Ceased
- 2015-10-23 CN CN201580057722.3A patent/CN107074804B/zh active Active
- 2015-10-23 ME MEP-2019-363A patent/ME03754B/me unknown
- 2015-10-23 PT PT157904087T patent/PT3209651T/pt unknown
- 2015-10-23 ES ES15790408T patent/ES2761903T3/es active Active
- 2015-10-23 MA MA40302A patent/MA40302B1/fr unknown
-
2017
- 2017-04-19 IL IL251798A patent/IL251798B/en active IP Right Grant
- 2017-04-20 PH PH12017500724A patent/PH12017500724A1/en unknown
- 2017-04-21 CL CL2017001001A patent/CL2017001001A1/es unknown
- 2017-05-04 CO CONC2017/0004517A patent/CO2017004517A2/es unknown
-
2019
- 2019-04-10 US US16/289,878 patent/US10676434B2/en active Active
- 2019-12-06 HR HRP20192197TT patent/HRP20192197T2/hr unknown
-
2020
- 2020-01-17 CY CY20201100040T patent/CY1122549T1/el unknown
- 2020-04-27 US US16/859,103 patent/US11053197B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017004517A2 (es) | Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration | |
UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
WO2015193740A3 (en) | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor | |
UY35369A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
CR20160537A (es) | Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico | |
CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
UY35625A (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa | |
AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
EA201790870A1 (ru) | Трициклические атропоизомерные соединения | |
CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
CL2018000391A1 (es) | Combinaciones farmacéuticas y su uso | |
ECSP18056196A (es) | Derivados de indano |